Renal Cancer - Results from #2040

Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology study. May 10, 2021

Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. May 7, 2021

Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers. May 7, 2021

Partial nephrectomy in frail patients: Benefits of robot-assisted surgery. May 6, 2021

MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma. May 6, 2021

DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers. May 5, 2021

Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis. May 5, 2021

Safety and oncologic efficacy of percutaneous MRI-guided cryoablation of intraparenchymal renal cancers. May 4, 2021

Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review. May 4, 2021

Irreversible Electroporation for the Treatment of Small Renal Masses: 5-Year Outcomes. May 3, 2021

The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments. May 3, 2021

Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies. April 30, 2021

Can texture analysis based on single unenhanced CT accurately predict the WHO/ISUP grading of localized clear cell renal cell carcinoma? April 30, 2021

Current and future perspectives on functional molecular imaging in nephro-urology: theranostics on the horizon. April 29, 2021

Reoperative Partial Nephrectomy: Does Previous Surgical Footprint Impact Outcomes? April 29, 2021

Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. April 28, 2021

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups. April 28, 2021

Pathological characteristics of the large renal mass: potential implication for clinical role of renal biopsy. April 27, 2021

PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. April 27, 2021

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. April 26, 2021

Page 103 of 456